Abhishek Jha

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3108416/publications.pdf

Version: 2024-02-01

215	11,220	46984 47	34964 98
papers	citations	h-index	g-index

231	231	231	9263
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Personalized Management of Pheochromocytoma and Paraganglioma. Endocrine Reviews, 2022, 43, 199-239.	8.9	127
2	Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using ⁶⁸Ga-DOTATATE, FDG, ¹⁸F-FDOPA, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 69	0.0	12
3	Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma. Journal of the National Cancer Institute, 2022, 114, 130-138.	3.0	21
4	Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. World Journal of Urology, 2022, 40, 385-390.	1.2	8
5	New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications. Cancers, 2022, 14, 594.	1.7	33
6	Functional Imaging of Neuroendocrine Tumors: Stacking the Odds in a Patientâ€™s Favor. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3953-e3954.	1.8	2
7	Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma. Cancer Research, 2022, 82, 2403-2416.	0.4	10
8	Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis. European Journal of Endocrinology, 2022, 187, 185-196.	1.9	1
9	Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations. Lancet Diabetes and Endocrinology,the, 2021, 9, 2-3.	5.5	6
10	Maintaining Professional Encounters and Enhancing Telemedicine Interactions With Core Virtual-Clinical Values. Endocrine Practice, 2021, 27, 77-79.	1.1	4
11	What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?. Endocrine Pathology, 2021, 32, 134-153.	5.2	22
12	A case of Carney triad complicated by renal cell carcinoma and a germline SDHA pathogenic variant. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.2	2
13	Developmental vascular malformations in EPAS1 gain-of-function syndrome. JCI Insight, 2021, 6, .	2.3	14
14	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2021, 27, 2989-2995.	3.2	42
15	Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 3455.	1.8	7
16	Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. Frontiers in Endocrinology, 2021, 12, 589451.	1.5	25
17	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. Frontiers in Endocrinology, 2021, 12, 625312.	1.5	25
18	Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?. Journal of Nuclear Medicine, 2021, 62, 1347-1348.	2.8	3

#	Article	IF	Citations
19	Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. Cancer Immunology, Immunotherapy, 2021, 70, 3303-3312.	2.0	5
20	Systemic Immune Response in Murine Bilateral Pheochromocytoma Model During Immunotherapy Based on a Combination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibodies (MBTA Therapy). Journal of the Endocrine Society, 2021, 5, A1032-A1033.	0.1	0
21	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. Cancers, 2021, 13, 3312.	1.7	9
22	Imaging of Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2021, 62, 1033-1042.	2.8	50
23	Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma. Cancers, 2021, 13, 3769.	1.7	3
24	A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. Journal of Nuclear Medicine, 2021, 62, 26S-33S.	2.8	8
25	Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. Cancers, 2021, 13, 3942.	1.7	7
26	Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma. Frontiers in Endocrinology, 2021, 12, 731096.	1.5	5
27	Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2021, 51, 519-528.	2.5	11
28	A long noncoding RNAâ€“microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. Endocrine, 2021, , 1.	1.1	1
29	Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. Journal of Nuclear Medicine, 2021, 62, 1192-1199.	2.8	14
30	Intravitreous treatment of severe ocular von <scp>Hippelâ€“Lindau</scp> disease using a combination of the <scp>VEGF</scp> inhibitor, ranibizumab and <scp>PDGF</scp> inhibitor, <scp>E10030</scp>: Results from a phase 1/2 clinical trial. Clinical and Experimental Ophthalmology, 2021, 49, 1048-1059.	1.3	5
31	A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy. Endocrine-Related Cancer, 2021, 28, 731-744.	1.6	9
32	Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI. European Journal of Radiology, 2021, 143, 109911.	1.2	3
33	The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. American Journal of Roentgenology, 2021, 217, 1008-1009.	1.0	1
34	Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. Molecules, 2021, 26, 6567.	1.7	4
35	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. International Journal of Cancer, 2020, 146, 2326-2335.	2.3	14
36	Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome. JAMA Ophthalmology, 2020, 138, 148.	1.4	4

#	Article	IF	Citations
37	Some Considerations in Treating Malignant Head and Neck Paragangliomas. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 209.	1.2	2
38	Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1176-1185.	1.8	18
39	Tentorial Venous Anatomy: Variation in the Healthy Population. American Journal of Neuroradiology, 2020, 41, 1825-1832.	1.2	3
40	Phosphoprotein-based biomarkers as predictors for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18401-18411.	3.3	25
41	Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumorsâ€"gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors. Human Pathology, 2020, 103, 72-82.	1.1	27
42	Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma. Journal of the American College of Cardiology, 2020, 76, 451-464.	1.2	30
43	Catecholamine physiology and its implications in patients with COVID-19. Lancet Diabetes and Endocrinology,the, 2020, 8, 978-986.	5.5	49
44	Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Current Treatment Options in Oncology, 2020, 21, 85.	1.3	43
45	Phaeochromocytoma â€" advances through science, collaboration and spreading the word. Nature Reviews Endocrinology, 2020, 16, 621-622.	4.3	8
46	Neuraxial dysraphism in EPAS1-associated syndrome due to improper mesenchymal transition. Neurology: Genetics, 2020, 6, e414.	0.9	5
47	Therapeutic Targeting ofSDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. Clinical Cancer Research, 2020, 26, 3868-3880.	3.2	29
48	Molecular Imaging in the Era of Precision Medicine: Paraganglioma as a Template for Understanding Multiple Levels of Analysis. Journal of Nuclear Medicine, 2020, 61, 646-648.	2.8	1
49	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.3	190
50	Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1051-1063.	1.2	30
51	Clinical manifestations of Pacakâ€Zhuang syndrome in a male pediatric patient. Pediatric Blood and Cancer, 2020, 67, e28096.	0.8	4
52	Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. Nuclear Medicine and Molecular Imaging, 2020, 54, 48-52.	0.6	9
53	Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma. Cancers, 2020, 12, 280.	1.7	23
54	Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes. Journal of Nuclear Medicine, 2020, 61, 643-645.	2.8	7

#	Article	IF	Citations
55	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. Journal of Bone and Mineral Research, 2020, 36, 315-321.	3.1	9
56	Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. Frontiers in Endocrinology, 2020, 11, 587065.	1.5	4
57	Comprehensive review of evaluation and management of cardiac paragangliomas. Heart, 2020, 106, 1202-1210.	1.2	22
58	A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/â˜ rats. Endocrine-Related Cancer, 2020, 27, 337-354.	1.6	16
59	HIF2Î± supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocrine-Related Cancer, 2020, 27, 625-640.	1.6	33
60	Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surgery, 2020, 9, 105-123.	0.5	37
61	18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.2	4
62	Facial Nerve Canal Paraganglioma. Clinical Nuclear Medicine, 2020, 45, 982-983.	0.7	0
63	A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/â˜ rats. Endocrine-Related Cancer, 2020, 27, X9-X10.	1.6	0
64	Overexpression of a Neuronal Type Adenylyl Cyclase (Type 8) in Sinoatrial Node Markedly Impacts Heart Rate and Rhythm. Frontiers in Neuroscience, 2019, 13, 615.	1.4	38
65	Postoperative Management in Patients with Pheochromocytoma and Paraganglioma. Cancers, 2019, 11, 936.	1.7	25
66	Current expertsâ€™ views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2223-2224.	3.3	6
67	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2112-2137.	3.3	208
68	Adipocyte Î²-arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. Nature Communications, 2019, 10, 2936.	5.8	43
69	Pseudopheochromocytoma. Endocrinology and Metabolism Clinics of North America, 2019, 48, 751-764.	1.2	9
70	Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. Seminars in Oncology, 2019, 46, 385-392.	0.8	11
71	Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A ¹⁸Fâ€FDOPA PET/CT study. Head and Neck, 2019, 41, 1565-1571.	0.9	4
72	Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A ¹⁸Fâ€FDOPA PET/CT study in head and neck paragangliomas. Clinical Endocrinology, 2019, 91, 879-884.	1.2	3

#	Article	IF	Citations
73	Pheochromocytoma (PHEO) and Paraganglioma (PGL). Cancers, 2019, 11, 1391.	1.7	7
74	MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. Journal of Surgical Research, 2019, 243, 1-7.	0.8	11
75	Chiari Malformation Type 1 in EPAS1-Associated Syndrome. International Journal of Molecular Sciences, 2019, 20, 2819.	1.8	8
76	Gallbladder Paraganglioma Associated with SDHD Mutation: a Potential Pitfall on 18F-FDOPA PET Imaging. Nuclear Medicine and Molecular Imaging, 2019, 53, 144-147.	0.6	6
77	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2Î± in Pheochromocytoma Cells. Cancers, 2019, 11, 594.	1.7	24
78	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. Cancers, 2019, 11, 654.	1.7	21
79	A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2019, 30, 90-95.	5.2	14
80	GsÎ± deficiency in the dorsomedial hypothalamus leads to obesity, hyperphagia, and reduced thermogenesis associated with impaired leptin signaling. Molecular Metabolism, 2019, 25, 142-153.	3.0	8
81	A Necessity, not a Second Thought: Pre-Operative Alpha-Adrenoceptor Blockade in Pheochromocytoma Patients. Endocrine Practice, 2019, 25, 200-201.	1.1	1
82	Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2019, 9, 53.	1.3	39
83	Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE. Nuclear Medicine and Molecular Imaging, 2019, 53, 223-230.	0.6	9
84	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. Cancers, 2019, 11, 436.	1.7	33
85	Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?. Hormone and Metabolic Research, 2019, 51, 458-469.	0.7	51
86	Nonmosaic somatic HIF2A mutations associated with late onset polycythemiaâ€paraganglioma syndrome: Newly recognized subclass of polycythemiaâ€paraganglioma syndrome. Cancer, 2019, 125, 1258-1266.	2.0	11
87	The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. Hormone and Metabolic Research, 2019, 51, 419-436.	0.7	22
88	Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. JAMA Surgery, 2019, 154, 40.	2.2	34
89	Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. Annals of Surgery, 2019, 269, 741-747.	2.1	15
90	Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects. Hormone and Metabolic Research, 2019, 51, 414-418.	0.7	5

#	Article	IF	Citations
91	A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. European Journal of Endocrinology, 2019, 181, 301-309.	1.9	25
92	Genotypeâ€“phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. Endocrine-Related Cancer, 2019, 26, 539-550.	1.6	87
93	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocrine-Related Cancer, 2019, 26, R627-R652.	1.6	72
94	Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019, 163, 212-219.	0.2	15
95	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1574-1582.	1.8	27
96	Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. Cellular and Molecular Neurobiology, 2018, 38, 1099-1106.	1.7	27
97	Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. , 2018, 188, 168-175.		40
98	Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2018, 24, 3423-3432.	3.2	57
99	Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell and Tissue Research, 2018, 372, 393-401.	1.5	37
100	Genomic Landscape of Pheochromocytoma and Paraganglioma. Trends in Cancer, 2018, 4, 6-9.	3.8	71
101	Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. Clinical Medicine Insights: Oncology, 2018, 12, 117955491876336.	0.6	27
102	A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report. BMC Cancer, 2018, 18, 286.	1.1	15
103	Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 278-282.	3.3	28
104	Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 787-797.	3.3	64
105	New Challenges in Nuclear Endocrinology. Journal of Nuclear Medicine, 2018, 59, 573-574.	2.8	0
106	Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. Surgery, 2018, 163, 191-196.	1.0	32
107	Blood collection in unstressed, conscious, and freely moving mice through implantation of catheters in the jugular vein: a new simplified protocol. Physiological Reports, 2018, 6, e13904.	0.7	10
108	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. Cancers, 2018, 10, 518.	1.7	10

#	Article	IF	Citations
109	New insights on the pathogenesis of paraganglioma and pheochromocytoma. F1000Research, 2018, 7, 1500.	0.8	17
110	Psychological impact of von Hippel-Lindau genetic screening in patients with a previous history of hemangioblastoma of the central nervous system. Journal of Psychosocial Oncology, 2018, 36, 624-634.	0.6	4
111	Prospective evaluation of ⁶⁸Gaâ€<scp>DOTATATE PET</scp>/<scp>CT</scp> in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clinical Endocrinology, 2018, 89, 155-163.	1.2	11
112	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. Endocrine, 2018, 61, 216-223.	1.1	7
113	A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?. International Journal of Endocrinology, 2018, 2018, 1-14.	0.6	11
114	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	1.1	45
115	Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. Frontiers in Endocrinology, 2018, 9, 515.	1.5	82
116	Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies. PLoS ONE, 2018, 13, e0201303.	1.1	4
117	Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. Journal of Neurosurgery: Spine, 2017, 26, 501-506.	0.9	10
118	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
119	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. Langenbeck's Archives of Surgery, 2017, 402, 787-798.	0.8	4
120	PET Imaging for Endocrine Malignancies: From Woe to Go. Journal of Nuclear Medicine, 2017, 58, 878-880.	2.8	2
121	Mitochondrial Complex II: At the Crossroads. Trends in Biochemical Sciences, 2017, 42, 312-325.	3.7	192
122	Paraganglioma of the organ of Zuckerkandl associated with a somatic HIF2Î± mutation: A case report. Oncology Letters, 2017, 13, 1083-1086.	0.8	4
123	Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Scientific Reports, 2017, 7, 40822.	1.6	26
124	18F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 812-821.	3.3	20
125	The Evolving Role of Succinate in Tumor Metabolism: An ¹⁸F-FDGâ€“Based Study. Journal of Nuclear Medicine, 2017, 58, 1749-1755.	2.8	27
126	SDHB-related pheochromocytoma and paraganglioma penetrance and genotypeâ€“phenotype correlations. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1421-1435.	1.2	63

#	Article	IF	Citations
127	Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. Journal of Nuclear Medicine, 2017, 58, 1236-1242.	2.8	29
128	Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous18F-FDG-PET/MRI: A Single-Institution Retrospective Study. American Journal of Neuroradiology, 2017, 38, 899-907.	1.2	42
129	PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumorsâ€"Reply. JAMA - Journal of the American Medical Association, 2017, 318, 1614.	3.8	2
130	HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions. European Journal of Cancer, 2017, 86, 1-4.	1.3	16
131	New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. Trends in Endocrinology and Metabolism, 2017, 28, 807-817.	3.1	34
132	Metanephrines for Evaluating Palpitations and Flushing. JAMA - Journal of the American Medical Association, 2017, 318, 385.	3.8	11
133	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Endocrine Reviews, 2017, 38, 489-515.	8.9	241
134	Recent advances in the imaging of pheochromocytomas and paragangliomas. International Journal of Endocrine Oncology, 2017, 4, 137-144.	0.4	0
135	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	1.2	63
136	A Large Adrenal Tumor With Marked 18F-Fluorodeoxyglucose Uptake. JAMA - Journal of the American Medical Association, 2017, 318, 84.	3.8	1
137	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. Endocrine Pathology, 2017, 28, 302-307.	5.2	25
138	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery, 2017, 161, 230-239.	1.0	60
139	Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice. Endocrine Pathology, 2017, 28, 2-6.	5.2	19
140	Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Surgery, 2017, 161, 220-227.	1.0	47
141	Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. Endocrinology, 2017, 158, 3097-3108.	1.4	10
142	Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. Oncotarget, 2017, 8, 22313-22324.	0.8	29
143	Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget, 2017, 8, 56110-56125.	0.8	64
144	18F-DOPA: the versatile radiopharmaceutical. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1187-1189.	3.3	15

#	Article	IF	Citations
145	Hypoxia-Inducible Factor 2Î± Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. Neoplasia, 2016, 18, 567-576.	2.3	16
146	The Author's Reply: inappropriate adrenoreceptor blockade prior to pheochromocytoma removal â€“ â€˜A timely reappraisalâ€™. Clinical Endocrinology, 2016, 85, 990-991.	1.2	0
147	Nuclear Medicine in Cancer Theranostics: Beyond the Target. Journal of Nuclear Medicine, 2016, 57, 1659-1660.	2.8	14
148	Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. Journal of Nuclear Medicine, 2016, 57, 1949-1956.	2.8	119
149	Pheochromocytoma: The First Metabolic Endocrine Cancer. Clinical Cancer Research, 2016, 22, 5001-5011.	3.2	59
150	Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study. Endocrine Practice, 2016, 22, 302-314.	1.1	110
151	Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. Clinical Endocrinology, 2016, 85, 62-69.	1.2	14
152	Radiopharmaceuticals in paraganglioma imaging: too many members on board?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 391-393.	3.3	6
153	PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1784-1791.	3.3	138
154	Molecular Subtypes ofKIT/PDGFRAWild-Type Gastrointestinal Stromal Tumors. JAMA Oncology, 2016, 2, 922.	3.4	291
155	Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. Journal of Neuro-Oncology, 2016, 126, 473-481.	1.4	18
156	InÂvivo detection of catecholamines byÂmagnetic resonance spectroscopy: AÂpotential specific biomarker for the diagnosis of pheochromocytoma. Surgery, 2016, 159, 1231-1233.	1.0	10
157	Mass spectrometric quantification of salivary metanephrinesâ€”A study in healthy subjects. Clinical Biochemistry, 2016, 49, 983-988.	0.8	10
158	Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1248-1257.	3.3	96
159	Prospective Study of ⁶⁸Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Journal of Clinical Oncology, 2016, 34, 588-596.	0.8	287
160	⁶⁸Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. Journal of Nuclear Medicine, 2016, 57, 186-191.	2.8	148
161	Determination of the unmetabolised 18F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. Medical and Biological Engineering and Computing, 2016, 54, 103-111.	1.6	9
162	Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. European Journal of Human Genetics, 2016, 24, 569-573.	1.4	57

#	Article	IF	Citations
163	Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models. Oncotarget, 2016, 7, 40531-40545.	0.8	10
164	Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. Human Genome Variation, 2015, 2, 15053.	0.4	26
165	Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with lifeâ€threatening compressive symptoms. Head and Neck, 2015, 37, E205-8.	0.9	2
166	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	2.9	176
167	Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open, 2015, 5, e008248-e008248.	0.8	29
168	Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4498-4504.	1.8	60
169	Metabolome Profiling by HRMAS NMR Spectroscopy of Pheochromocytomas and Paragangliomas Detects SDH Deficiency: Clinical and Pathophysiological Implications. Neoplasia, 2015, 17, 55-65.	2.3	60
170	Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. Journal of the American College of Surgeons, 2015, 221, 509-517.	0.2	72
171	Pheochromocytoma: Gasping for Air. Hormones and Cancer, 2015, 6, 191-205.	4.9	26
172	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 167.e13-167.e20.	0.8	24
173	Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas. American Journal of Cardiology, 2015, 115, 1753-1759.	0.7	30
174	Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2015, 21, 3888-3895.	3.2	223
175	18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. Journal of Nuclear Medicine, 2015, 56, 1849-1854.	2.8	4
176	Carney triad, SDH-deficient tumors, and Sdhb+/â^' mice share abnormal mitochondria. Endocrine-Related Cancer, 2015, 22, 345-352.	1.6	23
177	Pendrin localizes to the adrenal medulla and modulates catecholamine release. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E534-E545.	1.8	23
178	Application and Dosimetric Requirements for Gallium-68â€"labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics, 2015, 10, 477-486.	1.5	14
179	Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology, 2015, 156, 4094-4104.	1.4	12
180	15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocrine-Related Cancer, 2015, 22, T135-T145.	1.6	84

#	Article	IF	Citations
181	Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. American Journal of Cancer Research, 2015, 5, 1558-70.	1.4	10
182	High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma. PLoS ONE, 2014, 9, e90458.	1.1	9
183	ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195. PLoS ONE, 2014, 9, e101423.	1.1	36
184	External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2014, 4, 166.	1.3	51
185	¹⁸Fâ€<scp>FDG PET</scp>/<scp>CT</scp> as a predictor of hereditary head and neck paragangliomas. European Journal of Clinical Investigation, 2014, 44, 325-332.	1.7	30
186	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. Urology, 2014, 83, 1225-1232.	0.5	40
187	Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans. Cell Metabolism, 2014, 19, 302-309.	7.2	643
188	Familial pheochromocytomas and paragangliomas. Molecular and Cellular Endocrinology, 2014, 386, 92-100.	1.6	47
189	Ocular Manifestations of Hypoxia-Inducible Factor-2Î± Paraganglioma-Somatostatinoma-Polycythemia Syndrome. Ophthalmology, 2014, 121, 2291-2293.	2.5	23
190	Current Approaches and Recent Developments in the Management of Head and Neck Paragangliomas. Endocrine Reviews, 2014, 35, 795-819.	8.9	124
191	The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer, 2014, 14, 523.	1.1	55
192	Association between acute sympathetic response, early onset vasospasm, and delayed vasospasm following spontaneous subarachnoid hemorrhage. Journal of Clinical Neuroscience, 2014, 21, 256-262.	0.8	17
193	Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomasâ€“Effect of Different Statins on Mouse Pheochromocytoma Cells. PLoS ONE, 2014, 9, e97712.	1.1	24
194	Commentary. Clinical Chemistry, 2013, 59, 1565-1565.	1.5	0
195	New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia. Journal of Clinical Oncology, 2013, 31, 1690-1698.	0.8	129
196	NFâ€ÎºB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. International Journal of Cancer, 2012, 131, 2445-2455.	2.3	34
197	Response to Letter to the Editor by Dullaart etÂal.. Clinical Endocrinology, 2010, 72, 569-570.	1.2	0
198	Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones, 2009, 8, 111-116.	0.9	36

#	Article	IF	Citations
199	Preoperative Management of the Pheochromocytoma Patient. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4069-4079.	1.8	497
200	Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes. Expert Review of Endocrinology and Metabolism, 2007, 2, 399-406.	1.2	2
201	An assessment of biochemical tests for the diagnosis of pheochromocytoma. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 744-745.	2.9	19
202	Phaeochromocytoma. Lancet, The, 2005, 366, 665-675.	6.3	1,462
203	The Role of [18F]Fluorodeoxyglucose Positron Emission Tomography and [111In]-Diethylenetriaminepentaacetate-d-Phe-Pentetreotide Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2214-2221.	1.8	133
204	Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer, 2004, 11, 423-436.	1.6	299
205	Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography. Endocrine Reviews, 2004, 25, 568-580.	8.9	145
206	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[18 F]Fluorodopamine Positron Emission Tomography. Journal of Urology, 2003, 169, 274-275.	0.2	24
207	Diagnostic Imaging of Pheochromocytoma. , 2003, 31, 107-120.		12
208	Chronic Hypercortisolemia Inhibits Dopamine Synthesis and Turnover in the Nucleus accumbens: An in vivo Microdialysis Study. Neuroendocrinology, 2002, 76, 148-157.	1.2	41
209	Diagnostic Localization of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 170-176.	1.8	60
210	Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene, 2001, 20, 7809-7811.	2.6	46
211	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	1.8	262
212	6-[¹⁸ F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma. Hypertension, 2001, 38, 6-8.	1.3	215
213	A â€œPheoâ€•Lurks: Novel Approaches for Locating Occult Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3641-3646.	1.8	51
214	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	1.8	81
215	Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches. Frontiers in Endocrinology, 0, 13, .	1.5	6